Evaluation of Drug–Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects

Clinical Drug Investigation

Volumn 38, Issue 11, 2018, Pages 1053-1060

  Kawaguchi, Nao ^a   Koshimichi, Hiroki ^a   Ishibashi, Toru ^a   Wajima, Toshihiro ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ASPARTATE AMINOTRANSFERASE; BALOXAVIR; BALOXAVIR MARBOXIL; LACTATE DEHYDROGENASE; OSELTAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; PRODRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTACT DERMATITIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG SAFETY; EVALUATION STUDY; HUMAN; HUMAN EXPERIMENT; INFESTATION; JAPANESE (PEOPLE); MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS INFECTION; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG INTERACTION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CROSS-OVER STUDIES; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; OSELTAMIVIR; PRODRUGS; YOUNG ADULT;

EID: 85053509785     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-018-0697-2     Document Type: Article

References (13)

1. Noshi T. Preclinical activity of baloxavir marboxil, a first-in-class endonuclease inhibitor for influenza. Shionogi & Co., Ltd., Osaka, Japan, 2014 (Data on file)
2. Kitano M, Yamamoto A, Noshi T, Kawai M, Yoshida R, Sato A, Shishido T, Naito A. Synergistic antiviral activity of S-033188/S-033447, a novel inhibitor of influenza virus cap-dependent endonuclease, in combination with neuraminidase inhibitors in vitro. Abstract presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases; 22-25 Apr 2017; Vienna
3. Fukao K, Ando Y, Noshi T, Kawai M, Yoshida R, Sato A, Shishido T, Naito A. Delayed oral dosing of S-033188, a novel inhibitor of influenza virus cap-dependent endonuclease, exhibited significant reduction of viral titer and prolonged survival in mice infected with influenza A virus. Abstract presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases; 22–25 Apr 2017; Vienna
4. Xofluza [package insert] (in Japanese). Shionogi & Co., Ltd., Osaka, Japan, 2018
5. Koshimichi H. Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase 1 study findings. Shionogi & Co., Ltd., Osaka, Japan, 2015 (Data on file)
6. Tamiflu [package insert]. F. Hoffmann-La Roche Ltd., Basel, Switzerland, 1999
7. George H, Joseph M, Penelope W. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999;37(6):471–84
8. Regina D, Bharat T, Enrico F, Pia S, Charles O, Penny W. Safety and pharmacology of oseltamivir in clinical use. Drug Saf. 2003;26(11):787–801
9. Morimoto K, Nakakariya M, Shirasaka Y, Kakinuma C, Fujita T, Tamai I, Ogihara T. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab Dispos. 2008;36(1):6–9
10. Ogihara T, Kano T, Wagatsuma T, Wada S, Yabuuchi H, Enomoto S, Morimoto K, Shirasaka Y, Kobayashi S, Tamai I. Oseltamivir (Tamiflu) is a substrate of peptide transporter 1. Drug Metab Dispos. 2009;37(8):1676–81
11. US Food and Drug Administration. Draft guidance: clinical drug interaction studies: study design, data analysis, and clinical implications, guidance for industry. Silver Spring, U.S.: U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2017
12. European Medicines Agency. Guideline on the investigation of drug interactions. London, U.K.: Committee for Human Medical Products (CHMP); 2012
13. Ministry of Health, Labour and Welfare. Draft guideline for drug–drug interactions. Tokyo, Japan: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau; 2017